ResMed Inc.

NYSE:RMD Stock Report

Market Cap: US$34.0b

ResMed Valuation

Is RMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RMD ($237.27) is trading below our estimate of fair value ($340.38)

Significantly Below Fair Value: RMD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RMD?

Key metric: As RMD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RMD. This is calculated by dividing RMD's market cap by their current earnings.
What is RMD's PE Ratio?
PE Ratio31.3x
EarningsUS$1.11b
Market CapUS$33.98b

Price to Earnings Ratio vs Peers

How does RMD's PE Ratio compare to its peers?

The above table shows the PE ratio for RMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.6x
IDXX IDEXX Laboratories
39x10.3%US$33.5b
GEHC GE HealthCare Technologies
21.5x11.5%US$35.4b
DXCM DexCom
45.9x16.6%US$29.6b
EW Edwards Lifesciences
28.2x3.3%US$43.6b
RMD ResMed
31.3x11.1%US$34.0b

Price-To-Earnings vs Peers: RMD is good value based on its Price-To-Earnings Ratio (31.3x) compared to the peer average (33.6x).

Price to Earnings Ratio vs Industry

How does RMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.9xn/aUS$8.04m
PAVM PAVmed
0.4x-90.0%US$6.65m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
RMD 31.3xIndustry Avg. 34.5xNo. of Companies9PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RMD is good value based on its Price-To-Earnings Ratio (31.3x) compared to the US Medical Equipment industry average (34.5x).

Price to Earnings Ratio vs Fair Ratio

What is RMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RMD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.3x
Fair PE Ratio35.2x

Price-To-Earnings vs Fair Ratio: RMD is good value based on its Price-To-Earnings Ratio (31.3x) compared to the estimated Fair Price-To-Earnings Ratio (35.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RMD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$237.27
US$253.11
+6.7%
9.7%US$283.00US$190.00n/a12
Dec ’25US$249.02
US$253.39
+1.8%
10.1%US$283.00US$190.00n/a11
Nov ’25US$244.28
US$253.39
+3.7%
10.1%US$283.00US$190.00n/a11
Oct ’25US$238.75
US$240.48
+0.7%
10.9%US$280.00US$180.00n/a11
Sep ’25US$245.02
US$232.83
-5.0%
7.8%US$264.00US$200.00n/a10
Aug ’25US$214.56
US$222.96
+3.9%
9.5%US$264.00US$180.00n/a10
Jul ’25US$186.94
US$220.42
+17.9%
9.9%US$264.00US$180.00n/a11
Jun ’25US$206.33
US$216.65
+5.0%
10.3%US$264.00US$180.00n/a12
May ’25US$215.01
US$215.05
+0.02%
10.3%US$264.00US$180.00n/a13
Apr ’25US$189.32
US$205.67
+8.6%
11.3%US$258.00US$164.00n/a13
Mar ’25US$174.61
US$204.98
+17.4%
11.1%US$258.00US$164.00n/a13
Feb ’25US$193.66
US$201.32
+4.0%
12.0%US$258.00US$164.00n/a12
Jan ’25US$172.02
US$185.36
+7.8%
15.5%US$258.00US$158.00n/a11
Dec ’24US$159.64
US$183.55
+15.0%
16.1%US$258.00US$158.00US$249.0211
Nov ’24US$147.18
US$189.31
+28.6%
17.0%US$258.00US$158.00US$244.2811
Oct ’24US$147.87
US$220.76
+49.3%
16.9%US$275.00US$170.00US$238.7511
Sep ’24US$159.19
US$247.71
+55.6%
8.5%US$275.00US$207.00US$245.0212
Aug ’24US$225.35
US$261.63
+16.1%
7.1%US$290.00US$221.00US$214.5612
Jul ’24US$218.50
US$259.79
+18.9%
6.7%US$290.00US$221.00US$186.9412
Jun ’24US$218.69
US$260.46
+19.1%
6.1%US$290.00US$229.00US$206.3312
May ’24US$234.43
US$258.18
+10.1%
5.1%US$280.00US$229.00US$215.0111
Apr ’24US$218.99
US$256.44
+17.1%
6.6%US$280.00US$219.00US$189.329
Mar ’24US$214.11
US$256.44
+19.8%
6.6%US$280.00US$219.00US$174.619
Feb ’24US$229.02
US$256.44
+12.0%
6.6%US$280.00US$219.00US$193.669
Jan ’24US$208.13
US$251.67
+20.9%
7.5%US$280.00US$211.00US$172.029
Dec ’23US$229.34
US$251.67
+9.7%
7.5%US$280.00US$211.00US$159.649

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 22:26
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ResMed Inc. is covered by 57 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterANZ Equities Pty Limited
Russell WrightAPP Securities Pty Ltd.
David RescottBaird